Metagenomi Therapeutics (MGX) Shares Outstanding (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Shares Outstanding (Entity) of $37.6 million for Q1 2026, up 0.71% year-over-year from $37.4 million in Q1 2025, and little changed quarter-over-quarter from $37.6 million in Q4 2025.
Metagenomi Therapeutics (MGX) Shares Outstanding (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Shares Outstanding (Entity) for 4 consecutive years, with $37.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 0.71% year-over-year to $37.6 million; the TTM figure through Mar 2026 stood at $37.6 million (up 0.71% YoY), while the FY2025 annual figure was $37.6 million, up 0.54% from the prior year.
- Shares Outstanding (Entity) steadied at $37.6 million in Q1 2026 per MGX's latest filing, from $37.6 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $37.6 million in Q1 2026 and bottomed at $3.4 million in Q1 2023.
- Historically, Shares Outstanding (Entity) has averaged $25.8 million across 4 years, with a median of $37.4 million in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) jumped 1000.28% — and 2025, when it climbed 0.2%.
- Metagenomi Therapeutics' Shares Outstanding (Entity) stood at $3.4 million in 2023, then soared by 999.06% to $37.4 million in 2024, then grew by 0.54% to $37.6 million in 2025, then advanced by 0.07% to $37.6 million in 2026.
- Business Quant data shows MGX's Shares Outstanding (Entity) at $37.6 million in Q1 2026, $37.6 million in Q4 2025, and $37.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 37.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.66 Mn |
| Mar 31, 2026 | 37.58 Mn |
| Dec 31, 2025 | 37.25 Mn |
| Sep 30, 2025 | 37.35 Mn |
| Jun 30, 2025 | 37.16 Mn |
| Mar 31, 2025 | 37.02 Mn |
| Dec 31, 2024 | 33.03 Mn |
| Sep 30, 2024 | 36.77 Mn |
| Jun 30, 2024 | 36.63 Mn |
| Mar 31, 2024 | 21.14 Mn |
| Dec 31, 2023 | 3.40 Mn |
| Sep 30, 2023 | 3.40 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 3.40 Mn |